Rhumbline Advisers Sells 8,590 Shares of Maximus, Inc. $MMS

Rhumbline Advisers cut its stake in Maximus, Inc. (NYSE:MMS) by 4.3% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 192,773 shares of the health services provider’s stock after selling 8,590 shares during the period. Rhumbline Advisers owned about 0.34% of Maximus worth $17,614,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in MMS. Reinhart Partners LLC. raised its stake in shares of Maximus by 0.8% in the third quarter. Reinhart Partners LLC. now owns 921,578 shares of the health services provider’s stock worth $84,206,000 after acquiring an additional 7,722 shares during the last quarter. Stephens Investment Management Group LLC increased its holdings in shares of Maximus by 49.0% in the third quarter. Stephens Investment Management Group LLC now owns 720,943 shares of the health services provider’s stock valued at $65,873,000 after purchasing an additional 237,097 shares in the last quarter. Federated Hermes Inc. raised its position in Maximus by 1.3% in the 3rd quarter. Federated Hermes Inc. now owns 688,505 shares of the health services provider’s stock worth $62,909,000 after purchasing an additional 8,847 shares during the last quarter. Norges Bank acquired a new position in Maximus during the 2nd quarter worth $47,886,000. Finally, Boston Partners lifted its holdings in Maximus by 113.6% during the 2nd quarter. Boston Partners now owns 657,247 shares of the health services provider’s stock worth $46,435,000 after buying an additional 349,529 shares in the last quarter. Institutional investors and hedge funds own 97.21% of the company’s stock.

Insider Transactions at Maximus

In other news, CFO David Mutryn purchased 1,000 shares of the business’s stock in a transaction dated Monday, February 9th. The shares were bought at an average cost of $75.62 per share, for a total transaction of $75,620.00. Following the completion of the acquisition, the chief financial officer directly owned 40,037 shares in the company, valued at approximately $3,027,597.94. This trade represents a 2.56% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Michelle F. Link sold 4,039 shares of the company’s stock in a transaction dated Wednesday, December 3rd. The stock was sold at an average price of $86.84, for a total value of $350,746.76. Following the transaction, the insider directly owned 19,542 shares of the company’s stock, valued at $1,697,027.28. This represents a 17.13% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders purchased 4,231 shares of company stock valued at $329,521 over the last quarter. Corporate insiders own 1.80% of the company’s stock.

Maximus Price Performance

MMS opened at $72.39 on Wednesday. The stock has a market cap of $3.95 billion, a P/E ratio of 11.02 and a beta of 0.57. Maximus, Inc. has a 12 month low of $63.77 and a 12 month high of $100.00. The company has a quick ratio of 2.34, a current ratio of 2.34 and a debt-to-equity ratio of 0.88. The company has a fifty day simple moving average of $88.73 and a 200 day simple moving average of $86.69.

Maximus (NYSE:MMS) last posted its earnings results on Thursday, February 5th. The health services provider reported $1.85 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.84 by $0.01. Maximus had a return on equity of 25.30% and a net margin of 6.92%.The firm had revenue of $1.35 billion during the quarter, compared to analysts’ expectations of $1.37 billion. During the same period in the previous year, the firm earned $1.61 earnings per share. The company’s revenue was down 4.1% on a year-over-year basis. Maximus has set its FY 2026 guidance at 8.050-8.350 EPS. On average, research analysts expect that Maximus, Inc. will post 6.15 EPS for the current year.

Maximus Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, March 2nd. Stockholders of record on Friday, February 13th will be issued a $0.33 dividend. This represents a $1.32 annualized dividend and a dividend yield of 1.8%. This is a boost from Maximus’s previous quarterly dividend of $0.30. The ex-dividend date is Friday, February 13th. Maximus’s dividend payout ratio is currently 20.09%.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on MMS shares. Zacks Research upgraded Maximus from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, December 30th. Wall Street Zen upgraded shares of Maximus from a “hold” rating to a “buy” rating in a research report on Sunday. Finally, Weiss Ratings reissued a “buy (b-)” rating on shares of Maximus in a research note on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating and one has issued a Buy rating to the company’s stock. According to MarketBeat.com, Maximus has an average rating of “Strong Buy”.

About Maximus

Maximus, Inc (NYSE: MMS) is a global provider of government services focused on delivering health and human services programs. The company partners with federal, state, and local agencies to administer and manage programs that support individuals and families across various stages of life. Key service areas include eligibility determination and enrollment services for Medicaid, Medicare, Children’s Health Insurance Program (CHIP) and other public assistance programs, as well as call center operations, case management and program integrity solutions.